Efficacy of ultramicronized palmitoylethanolamide in burning mouth syndrome-affected patients: a preliminary randomized double-blind controlled trial
Randomised controlled trialHumans
- Design
- Randomised controlled trial
- Subjects
- 35 patients enrolled. 29 completed.
- Dose used in the study
- 600 mg of ultramicronised palmitoylethanolamide twice a day
- Duration
- 60 days, with a follow-up 4 months after stopping
- What was measured
- Intensity of the burning sensation on a numeric rating scale, at day 30, day 60 and 4 months after treatment
What the authors reported
Burning sensation fell significantly more in the treatment group than with placebo at 60 days (p < 0.0132), with no treatment-related side effects observed.
Limits of this study
The authors call the trial preliminary. 35 patients were enrolled and 6 withdrew. The abstract does not give the funding or conflict of interest statements.
Source
PubMed 30361792 · doi:10.1007/s00784-018-2720-7
Entry checked against the abstract on PubMed on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.